Home Monitoring of Blood Sugar Did Not Improve Glycemic Control After 1 Year

Self-monitoring of blood glucose levels in patients with type 2 diabetes who are not treated with insulin did not improve glycemic control or health-related quality of life after one year in a randomized trial, results that suggest self-monitoring should not be routine in these patients, according to a new study published by JAMA Internal Medicine. The study has been presented at the American Diabetes Association 77th Scientific Sessions.

Many patients with type 2 diabetes not treated with insulin regularly perform self-monitoring of blood glucose (SMBG), although the value of that practice has been debated.

Katrina E. Donahue, M.D., M.P.H., and Laura A. Young, M.D., Ph.D., of the University of North Carolina at Chapel Hill, and coauthors conducted a trial in 15 primary care practices in North Carolina with 450 patients with non-insulin-treated type 2 diabetes. The patients were an average of 61 years old, had had diabetes for an average of eight years, and 75 percent were performing SMBG at baseline.

The patients were assigned to one of three groups: those who performed no SMBG, those who performed once-daily SMBG, and those who performed once-daily SMBG but received enhanced feedback messages delivered through their blood glucose meters.

The study measured hemoglobin A1c levels (a measure of longer-term blood sugar control) across all three groups and health-related quality of life after one year.

According to the results, there were no differences in glycemic control or health-related quality of life after one year between patients who performed SMBG compared with those who didn't.

Attrition in the SMBG monitoring groups could explain why some improvements were initially seen in hemoglobin A1c levels in the early months that weren't significant at 12 months, according to the study. The study also did not determine the effectiveness of SMBG in certain clinical situations, such as when a new medication is started or when a dose is changed.

The authors warn the results do not apply to patients with diabetes treated with insulin.

"Based on these findings, patients and clinicians should engage in dialogue regarding SMBG with the current evidence suggesting that SMBG should not be routine for most patients with non-insulin-treated T2DM [type 2 diabetes mellitus]," the article concludes.

Young LA, Buse JB, Weaver MA, Vu MB, Mitchell CM, Blakeney T, Grimm K, Rees J, Niblock F, Donahue KE, for the Monitor Trial Group.
Glucose Self-monitoring in Non–Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings A Randomized Trial.
JAMA Intern Med. Published online June 10, 2017. doi: 10.1001/jamainternmed.2017.1233.

Most Popular Now

Zebra Announces Regulatory Approval of i…

Zebra Medical Vision, the leading machine learning imaging analytics company, announces that the company has been granted the CE approval and subsequent release of its Deep Learning Analytics Engine in...

Mind-Controlled Device Helps Stroke Pati…

Stroke patients who learned to use their minds to open and close a device fitted over their paralyzed hands gained some control over their hands, according to a new study...

Philips and Illumina Team Up with Navica…

Royal Philips (NYSE: PHG, AEX: PHIA) and Navican, an Intermountain Healthcare company, today signed an agreement to deploy a precision health informatics solution that will allow hospitals and health systems...

NHS Organisations to Access IMS MAXIMS C…

Award-winning electronic patient record (EPR) provider IMS MAXIMS has announced the availability of its cloud services on the latest iteration of the UK Government's G Cloud Framework. NHS organisations looking...

Boehringer Ingelheim Builds Digital Lab …

With the founding of BI X as independent subsidiary Boehringer Ingelheim will focus on breakthrough innovative digital solutions in healthcare from idea to pilot. The start-up will work closely together...

Artificial Intelligence to Assist in the…

The University of Tampere and TAYS (Tampere University Hospital) Heart Hospital use artificial intelligence (A.I.) technologies developed by VTT Technical Research Centre of Finland in the home care of heart...

Anyone can Become More Curious. Is that …

Merck, a leading science and technology company, today announced the start of an experiment entitled "Anyone can become more curious". Driven by the company’s curiosity initiative, which measured and described...

EC Open Call FETOPEN-01-2016-2017: FET-O…

The successful exploration of new foundations for radically new future technologies requires supporting a large set of early stage, high risk visionary science and technology projects to investigate new ideas...

Home Monitoring of Blood Sugar Did Not I…

Self-monitoring of blood glucose levels in patients with type 2 diabetes who are not treated with insulin did not improve glycemic control or health-related quality of life after one year...

Call for Applications: 2017 Lyfebulb-Nov…

For the second year in a row, Lyfebulb and Novo Nordisk will support international patient entrepreneurs who develop innovative ideas and concepts aimed to positively empower and impact the lives...

New Cellular Imaging Paves Way for Cance…

Researchers at the Universities of York and Leiden have pioneered a technique which uses florescent imaging to track the actions of key enzymes in cancer, genetic disorders and kidney disease...

UK PACS Win for Carestream Announced

West Hertfordshire Hospitals NHS Trust (West Herts) located in the South East of the UK and Carestream have signed and exchanged contracts to replace the Trust's existing PACS with a...